Trial Profile
Interventional, Randomized, Open-label, Three-group, Two-sequence Crossover, Single-dose, Bioequivalence Study of Lu AF35700 in Healthy Subjects Comparing the 5, 10 and 20 mg Commercial Tablet (Test) to the 5, 10 and 20 mg Clinical Tablet (Reference)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs LU AF-35700 (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Lundbeck A/S
- 28 Nov 2018 Status changed from recruiting to completed.
- 23 Aug 2018 Planned End Date changed from 13 Jul 2018 to 5 Oct 2018.
- 23 Aug 2018 Planned primary completion date changed from 20 Jun 2018 to 5 Oct 2018.